Researchers in the United States have reported promising results from a personalised cancer vaccine designed to prevent melanoma from returning or spreading.
The vaccine, known as intismeran autogene, is being developed by Moderna, a biotechnology company, in partnership with Merck, a biopharmaceutical company.
It is designed for patients with high-risk melanoma after their tumours have been surgically removed, Reuters reported.
According to the National Cancer Institute (NCI), melanoma is less common than other major types of skin cancer but is more likely to invade nearby tissue and spread to other parts of the body. Most deaths from skin cancer are caused by melanoma.
The American Cancer Society estimates roughly 112,000 new cases of invasive melanoma and 8,510 deaths for 2026.
